Medinol’s EluNIR-PERL Drug-Eluting Coronary Stent System Receives the US FDA’s Approval to Treat Coronary Artery Disease
Shots:
- The approval for distribution across the US was granted based on the clinical data from the evaluation of Medinol’s EluNIR DES system in patients with coronary artery disease
- EluNIP-PERL is the latest addition to the company’s EluNIR DES family which contains four radiopaque markers (two at each end of the stent) along with a hybrid polymer-metal radiopaque catheter tip
- The features of the EluNIP-PERL system aid during PCI procedures providing meaningful advantage to surgeons, precise stent placement, shorter procedure times & reduced radiation exposure. Additionally, EluNIR-PERL is made available across the US through CoSo Health by leveraging its SaaS+ platform to reduce the layer in supply chain
Ref: PR Newswire | Image: Medinol
Related News:- AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
